Long-term higher doses of inhaled corticosteroids may increase diabetes risk in COPD patients
A recent systematic review and meta-analysis examining the impact of inhaled corticosteroids (ICS) on diabetes risk among Chronic Obstructive Pulmonary Disease (COPD) patients found compelling evidence indicating a potential association between long-term ICS use, particularly at higher doses, and an increased risk of developing diabetes. This study was published in Tzu Chi Medical Journal by Kholis F N and colleagues.
The study, conducted through a systematic search across PubMed, EBSCOhost, and ProQuest databases from 2013 to 2023, included a total of 14 studies comprising 10 randomized controlled trials (RCTs) and 4 observational studies. The meta-analysis, following PRISMA 2020 guidelines, aimed to comprehensively assess the relationship between ICS use, diabetes risk, and blood glucose levels in COPD patients.
The analysis of RCTs did not yield a statistically significant increase in blood glucose levels after a 52-week follow-up period (odds ratio [OR] 1.07, 95% confidence interval [CI] 0.88-1.30). However, the observational studies suggested a tendency toward an elevated risk of diabetes (OR 1.40, 95% CI 0.96-2.03). Notably, a subgroup meta-analysis focusing on high-dose ICS (>900 μg/day) revealed a significant increase in the risk of diabetes (OR 1.20, 95% CI 1.09-1.32).
Researchers emphasized that while short-term use of ICS did not display a significant impact on blood glucose levels, prolonged and high-dose utilization showed a concerning association with an elevated risk of developing diabetes among COPD patients.
The findings underscore the need for careful consideration when prescribing long-term ICS treatment to COPD patients, particularly at higher doses, given the potential risk of adverse metabolic effects. These results prompt a reevaluation of treatment strategies, urging healthcare professionals to balance the benefits of ICS therapy against the potential risk of exacerbating diabetes in this patient population.
Reference:
Fathur Nur Kholisa, Kevin Gracia Pratamab*, Jessica Novia Hadiyanto. Association between inhaled corticosteroid use and risk of hyperglycemia in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Tzu Chi Medical Journal 2023; 35(4):355-361
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.